Author:
Lopes Luciana B.,Apolinário Alexsandra C.,Salata Giovanna C.,Malagó Isabella D.,Passos Julia S.
Publisher
Springer International Publishing
Reference171 articles.
1. (FDA), F. A. D. A. (2018). Liposome drug products: Chemistry, manufacturing, and controls; Human products pharmacokinetics and bioavailability; and labeling documentation. [Online]. Available: http://www.fda.gov/media/70837/download. Accessed 4 Jan 2022.
2. Abumanhal-Masarweh, H., Da Silva, D., Poley, M., Zinger, A., Goldman, E., Krinsky, N., Kleiner, R., Shenbach, G., Schroeder, J. E., Shklover, J., Shainsky-Roitman, J., & Schroeder, A. (2019). Tailoring the lipid composition of nanoparticles modulates their cellular uptake and affects the viability of triple negative breast cancer cells. Journal of Controlled Release, 307, 331–341.
3. Ağardan, N. B. M., Değim, Z., Yilmaz, Ş., Altintaş, L., & Topal, T. (2020). Tamoxifen/raloxifene loaded liposomes for oral treatment of breast cancer. Journal of Drug Delivery Science and Technology, 57, 101612.
4. Altamimi, M. A., Hussain, A., Alrajhi, M., Alshehri, S., Imam, S. S., & Qamar, W. (2021a). Luteolin-loaded elastic liposomes for transdermal delivery to control breast cancer: In Vitro and Ex Vivo evaluations. Pharmaceuticals (Basel), 14(11), 1143.
5. Altamimi, M. A., Hussain, A., Alshehri, S., Imam, S. S., & Alnemer, U. A. (2021b). Development and evaluations of transdermally delivered luteolin loaded cationic nanoemulsion: In Vitro and Ex Vivo evaluations. Pharmaceutics, 13(8), 1218.